Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target
Needham analyst Rajvindra Gill reiterates Microchip Technology (NASDAQ:MCHP) with a Buy and maintains $110 price target.
‘MongoDB’s Consumption Model Could Show Better Signs Of Resilience Versus Peers,’ Analyst Says
Citigroup analyst Tyler Radke maintains MongoDB Inc (NASDAQ:MDB) with a Buy and lowers the price target from $300 to $295. The analyst…
Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
Guidewire Software Wins Conviction As Top Pick Courtesy Market Leadership & Cloud Transition, Analyst Says
RBC Capital analyst Rishi Jaluria reiterates Guidewire Software, Inc. (NYSE: GWRE) with an
Dine Brands Analyst Says Underlying Trends Are Bit Difficult To Discern Given Omicron Laps In Recent Months
Raymond James analyst Brian M.Vaccaro reiterated a Market Perform rating on the shares of Dine Brands Global, Inc. (NYSE:DIN). Dine Brands reported a 9.4%…
Nutanix’s Internal Investigation Limits Outlook, Still Analysts Expect Minimal Impact, Remain Optimistic On Moderate Deal Elongation
Needham analyst Mike Cikos reiterates Nutanix Inc (NASDAQ: NTNX)
EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $11 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $11 price target.
Cantor Fitzgerald Reiterates Overweight on Allakos, Maintains $7 Price Target
Cantor Fitzgerald analyst Jennifer Kim reiterates Allakos (NASDAQ:ALLK) with a Overweight and maintains $7 price target.